

# **POSTER PRESENTATION**

**Open Access** 

# Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma

Steven F Weinstein<sup>1\*†</sup>, Kevin R Murphy<sup>2</sup>, Jonathan Corren<sup>3</sup>, Hendrik Nolte<sup>4</sup>, Martha V White<sup>5</sup>

From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2010 Victoria, Canada. 4-7 November 2010

# **Background**

Multiple strengths of mometasone furoate/formoterol (MF/F) MDI combination therapy are under investigation as new treatments for asthma. We report efficacy/ safety findings from a 3-month MF/F study in subjects with severe asthma.

## Materials and methods

This was a 3-month, randomized, double-blind, parallel-group, multicenter study with a 2-3-week open-label, run-in period of mometasone furoate (MF) 400  $\mu g$  twice-daily (BID). Subjects (>12 years) were randomized to MF/F (200/10  $\mu g$  or 400/10  $\mu g$  BID) or MF (400  $\mu g$  BID). The primary endpoint was the area under the curve (AUC) of the change in serial FEV $_1$  (0-12 hours) for MF/F 400/10  $\mu g$  vs MF 400  $\mu g$  from baseline to Week 12. Adverse events (AEs) and other clinical safety measures were recorded.

### Results

A total of 728 subjects (mean: age = 47.9 y, asthma duration = 14.0 y, FEV $_1$  % predicted = 66.3, reversibility = 22.9%, Asthma Control Questionnaire [ACQ] score = 1.93) were randomized. Improvements in mean changes from baseline in FEV $_1$  AUC $_{0-12~h}$  (L × h) at Week 12 were MF/F 200/10 µg = 3.59, MF/F 400/10 µg = 4.19, and MF 400 µg = 2.04, with both MF/F doses significantly better than MF (p < 0.001). These FEV $_1$ s

correspond to average hourly increases of 0.30, 0.35, and 0.17 L, respectively. MF/F was associated with rapid (<5 min) and sustained improvement in lung function. The percentage of subjects experiencing asthma deterioration (ie, severe asthma exacerbation) was 12.4% (MF/F 200/10  $\mu g$ ), 12.2% (MF/F 400/10  $\mu g$ ), and 18.3% (MF 400  $\mu g$ ). There were no notable differences in AEs between the groups.

# **Conclusions**

Both medium- and high-dose MF/F combination therapy led to significantly greater improvements in lung function compared with high-dose MF monotherapy in severe asthmatics.

### Author details

<sup>1</sup>llergy and Asthma Specialists Medical Group and Research Center, Huntington Beach, CA, 92647, USA. <sup>2</sup>Boys Town National Research Hospital, Boys Town, NE, 68130, USA. <sup>3</sup>Allergy Medical Clinic, Research Division, Los Angeles, CA, 90025, USA. <sup>4</sup>Merck Research Laboratories, Kenilworth, NJ, 07033, USA. <sup>5</sup>Institute for Asthma and Allergy, Wheaton, MD, 20902, USA.

Published: 22 December 2010

### doi:10.1186/1710-1492-6-S2-P34

Cite this article as: Weinstein et al.: Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma. Allergy, Asthma and Clinical Immunology 2010 6(Suppl 2):P34.

Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: sfwocallergy.com

<sup>†</sup> Contributed equally

<sup>&</sup>lt;sup>1</sup>llergy and Asthma Specialists Medical Group and Research Center, Huntington Beach, CA, 92647, USA